Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetrabenazine for tardive dyskinesia in psychiatric patients
IRCT20240308061212N1Phase 3Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of tetrabenazine in tardive dyskinesia (TD) (2 arms), sponsored by Zanjan University of Medical Sciences. Primary endpoint: Elimination of dyskinesia. Started Apr 2024; status: completed.
02
Drugs
tetrabenazine
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on IRCT20240308061212N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240308061212N1.